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ROLES AND MECHANISMS OF THE KIDNEY SODIUM-CHLORIDE 
COTRANSPORTER (NCC) IN SALT-SENSITIVE HYPERTENSION  
AKSHAY NILESH DESAI 
ABSTRACT 
 Hypertension is both a domestic and international health issue – diagnosed in 1 in 
3 U.S. adults and classified by the World Health Organization as the number one risk 
factor for mortality worldwide. It has been established that salt plays a role in the 
development of hypertension, and that a salt-sensitive phenotype indicates heightened 
sensitivity to salt consumption. Here, we studied the roles of the afferent renal nerves, 
which travel from the kidney to the central nervous system, and the sodium-chloride 
cotransporter in fluid and electrolyte homeostasis and blood pressure regulation.  
Our laboratory utilized a novel technique of afferent renal nerve ablation on 
Sprague-Dawley rats to examine the effects of afferent renal nerve mechanoreceptors and 
chemoreceptors in response to acute sympathoinhibitory challenges. Additionally, salt-
sensitive and salt-resistant rats were randomly subjected to chronic normal salt (0.6% 
NaCl) or high salt (8% NaCl) diets, and examined for levels of norepinephrine and 
substance-P release. A different group of salt-resistant and salt-sensitive rats were 
subcutaneously infused with terazosin, a selective -1 adrenoreceptor antagonist, or 
propranolol, a selective -adrenoreceptor antagonist, and then randomly subjected to 
normal salt (0.6% NaCl) or high salt (4% NaCl) diets for 21 days. We subsequently 
examined these rats, and analyzed the effects of high salt intake on blood pressure, 
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sodium-chloride cotransporter activity, and expression of the sodium-chloride 
cotransporter and its relevant kinases. 
In response to an acute mechanoreceptor-specific stimulus, Sprague-Dawley rats 
that underwent afferent renal nerve ablation were unable to modulate blood pressure or 
natriuresis after regaining consciousness. Chronic high salt (8% NaCl) consumption in 
salt-sensitive rats resulted in increased levels of plasma norepinephrine, renal 
norepinephrine, and norepinephrine-evoked Substance-P release. In addition, salt-
sensitive rats subjected to a 21-day high salt (4% NaCl) diet exhibited increased blood 
pressure, elevated sodium-chloride cotransporter activity, and upregulated levels of the 
sodium-chloride cotransporter and the kinases that regulate it. However, these observed 
increases in blood pressure, protein activity, and protein expression were abolished in 
salt-sensitive rats experiencing -1 adrenoreceptor antagonism due to terazosin 
administration.  
In conclusion, our findings indicate that mechanoreceptor-driven afferent renal 
nerve activation is needed to maintain fluid and electrolyte homeostasis and regulate 
blood pressure in response to acute sympathoinhibitory challenges and chronic high salt 
intake. In addition, our data demonstrates that the sodium-chloride cotransporter is 
aberrantly upregulated in salt-sensitive rats through a norepinephrine-1-adrenoreceptor 
gated pathway, and this this upregulation results in excessive salt reabsorption. Thus, our 
experiments have generated new data that reveals selective 1-adrenoreceptor 
antagonism and renal denervation as potential treatment options for hypertensive 
individuals. 
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INTRODUCTION 
History and Overview of Hypertension 
According to the World Health Organization (WHO), hypertension is the #1 risk 
factor for mortality worldwide1,2. It is common among Americans, affecting one in three 
adults in the United States1,2. Hypertension is also the #1 risk factor for disability-
adjusted life years, and is expected to affect 41% of all Americans by 20302–10. 
Furthermore, hypertension has been implicated as a major risk factor for many 
cardiovascular and renal diseases11. Stages of hypertension are classified by blood 
pressure. Table 1 indicates these classifications of blood pressure, as was established 
during The Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure12. 
Table 1: JNC 7 Blood Pressure Classification. (Taken from a the JNC 712) 
Blood Pressure Systolic Blood Pressure Diastolic Blood Pressure 
Classification mmHg mmHg 
Normal <120 and <80 
Prehypertension 120-139 or 80-89 
Hypertension Stage 1 140-159 or 90-99 
Hypertension Stage 2 > 160 or > 100 
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Though the classification of hypertension is relatively straightforward, its 
pathogenesis is more elaborate. Hypertension involves the incorporation of several 
important regulatory systems13, including the central nervous system (CNS). The CNS 
has been identified by multiple researchers as having a significant role in the 
development of hypertension14,15,16. In fact, it has been proposed that 50% of clinical 
hypertension cases are designated as neurogenic essential hypertension17.  
One key component of the CNS is the hypothalamus, which serves as a mediator 
and implementer of signal transduction in response to different stimuli18. Therefore, 
changes in the functioning capabilities of the hypothalamus can lead to changes in 
sympathetic nervous system activity which consequently affect other body functions. For 
example, parvocellular neurons in the paraventricular nucleus (PVN) influence 
sympathetic nervous activity (SNA) to mediate neural components of cardiovascular 
reflexes19–21. Figure 1, taken from a 2013 publication in Hypertension, shows the 
sympathetic nervous system and the brain sites that interact with it 18. 
Figure 1 – Sympathetic Nervous System Interactions with Specific Brain Sites. (From Hirooka et al. 
18). 
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History and Implications of Salt-Sensitive Hypertension 
Hypertension’s role as a risk factor in numerous cardiovascular and renal diseases 
makes it important to understand. One factor relevant to hypertension is salt, which is 
consumed in increasing quantities22 in the modern American diet. The kidney, which 
consists of many protein transporters that regulate sodium reabsorption, plays a 
significant role in sodium excretion. In fact, a hallmark of urinary tract obstruction is the 
failure of the kidney’s ability to regulate urinary excretion of water and sodium23–25. A 
long-term reduction in sodium intake has been clearly established to lower blood 
pressure26 and thus reduce the potential for cardiovascular risk. Furthermore, several 
studies have shown that a reduction in salt intake can reduce blood pressure in both 
hypertensive and normotensive patients27. 
There is great variability, however, in how different individuals respond to 
different quantities of salt intake28,29. A small increase in sodium intake may lead to 
drastic increases in blood pressure for certain individuals11, while others may experience 
little change despite consuming a significantly greater amount of sodium in their diet11.  
A formal definition of salt-sensitivity was given in 1996 by Dr. Myron 
Weinberger, who concluded that individuals are salt-sensitive if they exhibit a 10% 
increase in mean arterial pressure in response to a high salt (HS) vs low salt 
challenge11,30.  Approximately 50% of all hypertensive individuals are salt-sensitive31, 
while 26% of normotensive individuals are considered salt-sensitive32. Specific genetic 
polymorphisms have been identified that can predispose an individual to becoming salt-
sensitivity33. Specifically, genes that increase or decrease expression of proteins involved 
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in renal sodium transport are of interest. Gitelman’s Syndrome, for example, results from 
mutations in the sodium-chloride cotransporter (NCC) located at the distal convoluted 
tubule of the nephron (DCT)34–37. Individuals afflicted with this syndrome experience 
hypokalemia, hypomagnesemia, and metabolic alkalosis34–37. 
Figure 2, taken from a recent publication in Adv Exp Med Biol, illustrates findings 
from these many studies that demonstrate the effect of salt reduction on blood pressure in 
both hypertensive (A) and normotensive (B) patients 
Figure 2 – Effect of Salt Reduction on Blood Pressure in Hypertensive (A) and Normotensive Patients 
(B). (Taken from Rust et al.11) 
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Significance of the Afferent Renal Nerves in Salt Sensitive Hypertension  
The hypothalamus is not only integral for controlling blood pressure, but also for 
regulating fluid and electrolyte homeostasis. It is known that renal nerves conduct 
sympathetic nervous activity (RSNA), and play a crucial role in the regulation of the 
renin-angiotensin-aldosterone system (RAAS)18.  Once considered to be of little 
consequence by prominent physiologist Homer Smith, renal nerves have since been 
demonstrated to cause changes in many physiological parameters including arterial 
pressure, glomerular filtration rate, and renal blood flow38. These changes affect urinary 
sodium excretion (UNaV), also known as natriuresis, and demonstrate the impact that 
RSNA has on electrolyte homeostasis38. The importance of the renal nerves is further 
underscored by the fact that renal denervation leads to decreases in renal tubular sodium 
reabsorption and RAAS inhibition, resulting in overall decreases in blood pressure18. 
The afferent renal nerve (ARN) is also important in regulating RSNA. Originating 
in the kidney and projecting to nuclei such as the RVLM and PVN in the brainstem and 
hypothalamus39–41 respectively, the ARN functions as a negative feedback circuit42. The 
ARN conducts an inhibitory reno-renal reflex, which is activated by efferent (from brain 
to kidney) RSNA and/or chemical or mechanical stimuli42–44. This inhibitory reno-renal 
reflex suppresses both sodium reabsorption and efferent RSNA42,44–49. The ARN 
inhibitory reno-renal reflex requires the release of several important molecular 
compounds including prostaglandin E2, calcitonin g-related peptide, and substance P48–51. 
This inhibitory reno-renal reflex is conducted by renal -2 adrenoreceptors and both 
endothelin A and endothelin B (ETAR and ETBR) receptors48–51.  
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Animal models demonstrate the importance of the ARN. Spontaneously 
Hypertensive (SHR) rats model neurogenic hypertension, and have been shown to exhibit 
decreased -2-dependent adrenoreceptor activity48–51. Contrastingly, salt-resistant 
Sprague-Dawley (SD) rats exhibit increased ETBR dependent ARN activity during HS 
diets48–51. In fact, removal of all afferent renal inputs leads to salt-sensitive hypertension 
in normal SD rats52. Removal of ARN inputs via selective ARN ablation, however, 
remain of interest and are a focal point of current renal research. 
Significance of the Sodium-Chloride (NCC) Cotransporter  
Renal sodium reabsorption is carried out by protein transporters, one of which is 
the sodium-chloride cotransporter or NCC. The NCC belongs to a family of solute 
carriers in which electroneutrality is established through the simultaneous transport of 
both a cation and an anion in a 1:1 stoichiometric relationship53. The NCC is integral to 
the fine-tuning of sodium reabsorption that occurs after tubuloglomerular feedback, and it 
is responsible for the reabsorption of 5-10% of filtered sodium and potassium54,55. The 
rate at which the NCC transports sodium and chloride is generated and maintained by the 
sodium-potassium ATPase located at the basolateral membrane of renal tubular epithelial 
cells56.  
The NCC is sensitive to thiazides, a group of molecules that prevent sodium 
reabsorption by inhibiting sodium-chloride cotransporters (NCCs)53,56. Thiazides, such as 
Metolazone (MTZ) and Hydrochlorothiazide (HCTZ), prevent chloride reabsorption by 
NCCs located in the DCT56–58. There is significant evidence regarding the effectiveness 
of thiazides and thiazide diuretics in treating hypertension59–63, and they are widely 
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considered the first line of therapy for hypertension treatment64,65.  By inhibiting chloride 
reabsorption in the DCT, thiazide diuretics hamper the ability of NCCs to transport 
sodium and chloride ions simultaneously. Therefore, administration of thiazides causes 
attenuated sodium reabsorption. The NCC’s mechanism of action is illustrated by Figure 
3, taken from Dr. Gerardo Gamba’s 2009 publication in Am J Renal Physiol56. 
Figure 3 – Salt Reabsorption in the Early Part of the Distal Tubule of Nephron. DCT 1 – Distal 
Convoluted Tubule 1, DCT 2 – Distal Convoluted Tubule 2, NCC – Sodium-Chloride Cotransporter, 
ENaC – Epithelial Sodium Channel, CNT – Connecting Tubule. (From Gamba et al.56) 
  
It had been determined in the late 1980s that sodium and chloride transport 
occurred to a greater extent in the early distal tubule rather than the later distal tubule66. 
This increased transport is due to an increased density of solute transporters located in the 
early portion of the DCT56. This first portion of the DCT, designated as DCT 1, is 
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exclusively populated by NCC transporters, while the second portion, termed DCT 2, 
consists of both NCC and epithelial sodium channels (ENaC)56. Interestingly, the NCC 
directly regulates luminal potassium secretion and magnesium secretion, but inversely 
regulates calcium reabsorption56. Figures 4 and 5, taken from publications by Dr. Erika 
Moreno, illustrate the primary and secondary structure of the NCC cotransporter57,67. 
Figure 4 -  NCC Secondary Structure and Molecular Interactions. Na – Sodium ion, Cl – Chloride 
ion, MTZ – Metolazone (Thiazide diuretic). (From Moreno et al.57) 
Figure 5 – NCC Secondary Structure and Primary Structures in Human, Rat, Mouse, and Flounder 
NCC. (From Moreno et al.67) 
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The NCC and Salt-Sensitive Hypertension 
The relationship between salt-sensitive hypertension, the NCC, and excess RSNA 
has been of great interest. In 2011, a group of researchers analyzed the effects of salt 
intake on a protein known as With-No-Lysine kinase 4 (WNK4)68. WNK proteins have 
been identified as having significant roles in salt reabsorption69. These researchers, led by 
Dr. ShengYu Mu, determined that salt loading results in -adrenoreceptor mediated 
downregulation of WNK4, NCC activation in the DCT, and consequently increased salt 
retention and blood pressure68. A study conducted in 2014 delved deeper into NCC 
activation, analyzing the effect of norepinephrine (NE) on NCC activation and 
phosphorylation70. NE is an endogenous adrenergic compound that can increase blood 
pressure71. It has been established that NE mediates some of its effects by acting on 
adrenoreceptors located on renal tubular epithelial cells throughout the nephron38,70,72. 
 Using mice as a model, researchers analyzed the effects of a chronic infusion of 
NE. Their results suggested that NE may bind to both -1 and  adrenoreceptors in the 
aforementioned DCT 1 region, and that this binding affects WNK4 through activation of 
the protein kinase OxSR1 (Oxidative Stress Response Kinase 1)70. OxSR1 
phosphorylates NCC cotransporters, which stimulates them and increases their abundance 
at the apical membrane of tubular cells70. A phosphorylated NCC (pNCC) is active, and 
reabsorbs sodium and chloride70. Thus, substantial phosphorylation of NCC transporters 
causes increased sodium retention and, therefore, increased blood pressure70.  
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Figure 6, taken from Terker et al’s 2014 publication in Hypertension, illustrates 
the hypertensive effects of chronic NE infusion, which include increases in both NCC 
and pNCC levels in DCT tubular cells70.  
Figure 6 – Effects of Chronic Norepinephrine Infusion on Blood Pressure, NCC Abundance, and 
pNCC Abundance. A – Control vs NE chronic infusion effect on BP, B – NCC and actin levels in 
response to chronic NE infusion, C – pNCC-T53, WNK4, and actin levels in response to chronic NE 
infusion. (Reproduced from Terker et al.70) 
 
Through ARN ablation by exposure to capsaicin (Renal-CAP)73, our laboratory 
aims to demonstrate the ARN’s significant role in maintaining fluid and electrolyte 
homeostasis. Given the ARN’s role as a modulator of efferent RSNA, deficiencies in its 
ability to regulate sympathetic outflow can lead to increased sodium reabsorption, via the 
NCC, and increased risk of hypertension. Findings should indicate that the ARN’s 
mechanosensitive reno-renal reflex influences inhibition of excess RSNA. Further 
analyses will elucidate the mechanisms of the NCC, and detail more information 
concerning the signal transduction pathways it needs to function properly. Our data will 
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enrich pre-existing cardiovascular-renal research and highlight alternative therapeutic 
targets in sympathetically driven hypertension. 
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SPECIFIC AIMS 
 
 
1. To establish that mechanoreceptor-dependent afferent renal nerve activation 
facilitates fluid and electrolyte homeostasis and blood pressure regulation. 
 
2. To establish that NE regulates NCC activity, via an -1 adrenoreceptor gated 
WNK-OxSR1 signal transduction pathway, to mediate sodium homeostasis 
and long-term blood pressure regulation. 
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METHODS 
Animals 
Sprague–Dawley (SD), Dahl Salt-Sensitive (DSS), Dahl Salt-Resistant (DSR), 
Wistar-Kyoto (WKY), SHR (Envigo, Indianapolis, IN, USA), and Salt-Sensitive Brown 
Norway rats (SS-13-BN) (Charles River Laboratories, Wilmington, MA, USA) weighing 
275–300 g were individually housed in a temperature (range: 20–26 °C) and humidity-
controlled (range: 30–70%) environment under a 12-hour light/dark cycle and were 
randomly assigned to experimental treatment groups. Rats were allowed tap water and 
standard rodent diet (Test Diet, St. Louis, MO, USA) ad libitum. All experimental 
protocols were approved by the Institutional Animal Care and Use Committee in 
accordance with the guidelines of Boston University School of Medicine and the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. 
Generation of Salt-Sensitive Brown Norway (SS-13-BN) Rats 
The SS-13-BN rat line was derived at the Medical College of Wisconsin by using 
inbred normotensive Brown Norway (BN) rats and DSS rats. Residual heterozygosity and 
genetic contamination were eliminated by using a set of 182 microsatellite markers 
(Research Genetics) for genotyping that provided even coverage of the 21 chromosomes 
(10-cM intervals). The progenitor rats used for the present study were homozygous for all 
regions tested, and each of these parental strains underwent a periodic total genome scan 
to ensure allelic homogeneity.  
The generation of a panel of reciprocal SS-13-BN rats with the use of DSS and BN 
rats was initiated by using a single F1 male, originating from a male DSS rat and a female 
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BN rat, backcrossed to 2 or 3 DSS and BN females. For subsequent backcrosses, each 
selected male breeder was backcrossed to 3 to 6 parental females. DNA was extracted 
from tail tips of males and genotyped with markers spaced every 10 cM for the 
introgressed chromosome. Rats not heterozygous for the entire chromosome were 
rejected. Remaining male progeny were genotyped by using a subset of genetic markers 
that characterized the mixed chromosomes from the previous generation to select the best 
next breeders.  
This process was continued until there were no longer mixed chromosomes in the 
(recipient) genetic background. The rats carrying full-length heterozygous target 
chromosomes were crossed to fix the donor chromosome, and a total genome scan was 
performed to verify that the line was isogenic. The SS-13-BN line was then maintained by 
brother-sister matings. 
Surgical Procedures 
ARN Ablation by Exposure to Capsaicin (Renal-CAP) 
Rats were anesthetized, a midline abdominal incision was made, and the visceral 
organs were externalized and reflected to expose the left kidney. A hole was made in the 
peritoneal membrane to expose the renal artery and vein. The fat surrounding the renal 
artery and vein was then dissected away from the vessels to expose the renal nerves. A 
piece of gauze soaked in a capsaicin solution (33 mM in 5% ethanol, 5% Tween 80 and 
90% normal saline) was wrapped around the renal artery and vein for 15 minutes. A 
small piece of para-film was placed under the renal artery and vein before placement of 
the capsaicin-soaked gauze to prevent any nonrenal capsaicin exposure. After 15 minutes 
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of capsaicin exposure, the gauze and para-film were removed. The area was immediately 
dried, and the procedure was repeated on the contralateral side if necessary. At the end of 
the procedure, the viscera were replaced, and the abdominal muscles and skin were 
closed separately with 3– 0 silk suture. The sham control was performed by externalizing 
the viscera, visualizing the renal artery and vein, replacing the organs, and then closing 
the wound. 
Acute Femoral Artery, Vein, and Bladder Cannulation 
On day of study, all animals were anesthetized with sodium methohexital [20 
mg/kg intraperitoneally (ip)] and supplemented with 10 mg/kg intravenously as required. 
Once anesthetized, rats were instrumented with catheters in the left femoral artery, left 
femoral vein, and bladder for the measurement of arterial blood pressure, intravenous 
(IV) administration of saline and/or drugs, and renal function, respectively. Rats were 
subsequently placed in a Plexiglas holder, and an IV infusion of isotonic saline (20 
l/min) was maintained for a 2-hour recovery period before experimentation to allow the 
animal to regain full consciousness and to stabilize cardiovascular, renal, and excretory 
functions.  
Mean arterial pressure (MAP) and heart rate (HR) were recorded through the 
implanted femoral artery cannula using BIOPAC data acquisition software (MP150 and 
AcqKnowledge 3.8.2; BIOPAC Systems, Goleta, CA) connected to an external pressure 
transducer (P23XL; Viggo Spectramed, Oxnard, CA).  
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Subcutaneous Osmotic Minipump Implantation 
 
Animals were anesthetized (sodium methohexital, 20 mg/kg ip) and surgically 
instrumented with an osmotic minipump (Alzet, osmotic pump model 2ML2, Palo Alto, 
CA) that was placed subcutaneously in the subscapular region. After subcutaneous (sc) 
surgical placement, all animals were returned to their home cage following administration 
of penicillin (300,000 units/ml, 0.3 ml intramuscularly [im]). 
Experimental Treatment Groups 
Naïve Animals  
Naïve animals were randomly assigned to receive a NS (0.6% NaCl) or HS (4% 
or 8% NaCl) diet for a 21-day experimental period. WKY and SHR rats were kept on NS 
diet. 
Isotonic Saline Vehicle Infusion 
Animals underwent implantation of an osmotic minipump delivering a sc infusion 
of isotonic saline (flow rate 5 l/h) prior to random assignment to either a NS or HS diet 
for a 21-day experimental period. 
Norepinephrine Infusion  
Animals underwent implantation of an osmotic minipump delivering a sc infusion 
of NE (Sigma, St. Louis, MO; cat. no. A7256) dissolved in isotonic saline (NE; 600 
ng/min, flow rate 5 l/h74) prior to random assignment to either a NS or HS diet for a 21-
day experimental period. 
Terazosin Infusion 
Animals underwent implantation of an osmotic minipump delivering a sc infusion 
of the -1 adrenoreceptor antagonist terazosin (10mg/kg/day) dissolved in isotonic saline 
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prior to random assignment to either a NS or HS diet for a 21-day experimental period. 
Note in Figure 17, terazosin was administered from days 22-42 of the 42-day 
experimental period. 
Propranolol Infusion 
Animals underwent implantation of an osmotic minipump delivering a sc infusion 
of the -adrenoreceptor antagonist propranolol (10mg/kg/day) dissolved in isotonic saline 
prior to random assignment to either a NS or HS diet for a 21-day experimental period. 
Acute Experimental Protocols 
The following cardiovascular, intravenous, and renal sodium transporter activity 
were performed consecutively in a single experiment in each animal following 21 days of 
NS or HS intake. 
Cardiovascular Function 
Following a 2-hour surgical recovery period, baseline MAP was recorded 
continuously over a 30-minute period in conscious rats via the surgically implanted 
femoral artery cannula. 
Intravenous (iv) 5% Body Weight Volume Expansion 
 For a 30-minute period, rats underwent a 5% body weight (BW) volume 
expansion (VE) calculated [.05 x BW] IV isotonic saline administration. A 90-minute 
recovery period followed the VE administration. CV and renal parameters were 
monitored throughout. 
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2-Hour Intravenous (iv) 1M NaCl Infusion 
Following a 60-minute control period of IV saline, 1M NaCl was administered for 
2 hours (flow rate: 20 l/min). CV and renal parameters were continuously monitored, 
and a 2-hour recovery period followed. 
Renal Sodium Transporter Activity  
After cardiovascular function protocol concluded, renal sodium transporter 
activity was assessed. All animals received an IV infusion of isotonic saline (flow rate 20 
l/min) for 1-hour, followed by an IV bolus (2 mg/kg) of amiloride, which inhibits 
ENaC75–77, preceding a 1-hour IV infusion of amiloride (2 mg/kg, flow rate 20 l/min), 
and an IV bolus (2 mg/kg) of HCTZ, administered to inhibit NCC activity53,56, preceding 
a 1 hour IV infusion of amiloride (2 mg/kg, flow rate 20 l/min78) in combination with 
HCTZ (2 mg/kg, flow rate 20 l/min78).  
During the 3-hour protocol, HR and MAP were recorded and urine was collected 
in 10-minute intervals to assess peak natriuresis to IV amiloride or HCTZ (n = 6/group). 
The peak natriuretic response (UNaV; eq/min) was determined by subtracting the 
baseline UNaV value from the maximum natriuretic value observed during each hour of 
drug administration. Baseline UNaV values were determined by averaging the UNaV 
values from the last two 10-minute time points during the previous hours of the study 
[hour 1: IV saline (40–50 min, 50–60 min) or hour 2: IV amiloride (100–110 min, 110–
120 min)]. The maximum natriuretic response to amiloride occurred during the 10–20 
min time point after drug infusion. The maximum natriuretic response to amilorideHCTZ 
occurred during the 20–30 min time point following drug administration.  
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Analytical Techniques 
Urine volume was determined gravimetrically, assuming 1 g = 1 ml. Urinary and 
plasma sodium concentrations were measured using a flame photometer (model 943; 
Instrumentation Laboratories, Bedford, MA;).  
Plasma Norepinephrine (NE) Measurement  
 Naïve SD rats were placed on a NS or HS diet for the 21-day experimental 
protocol. After the protocol was completed, animals were decapitated while conscious 
and whole blood was collected. Plasma NE content was determined via ELISA (Immuno-
Biological Labs America, Minneapolis, MN; cat. no. IB89552). 
CNS Tissue Collection 
 At baseline and following completion of the IV VE or IV 2 hour 1M NaCl 
protocol (including recovery), rats were anaesthetized with sodium methohexital (10 mg 
kg iv) and immediately perfused transcardially with 0.2–0.3 L of 0.1 M phosphate-
buffered saline (PBS) followed by 4% paraformaldehyde (PFA) in 0.1 M PBS (4 °C, 0.3–
0.5 L). The brains were removed and placed in a vial containing 4% PFA in PBS 
overnight, and then switched to a 30% w/v sucrose solution for 2 days79. The PVN was 
sectioned into three separate sets of serial 40-m coronal sections that were collected into 
a cryoprotectant, consisting of 30% sucrose + 30% ethylene glycol + 1% polyvinyl-
pyrrolidone in 0.1 M PBS. These three sets were stored at 20 °C until they were 
processed for immunohistochemistry. 
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Fos+ Immunoreactivity  
Free-floating sections from each brain were processed for Fos 
immunohistochemistry using a rabbit polyclonal anti-Fos antibody (Calbiochem, San 
Diego, CA, USA) as previously described79. Sections were brought to room temperature 
and rinsed twice for 30 min in 0.1 M PBS to remove cryoprotectant. Sections were 
incubated in 0.3% hydrogen peroxide in distilled water for 30 min at room temperature 
and then rinsed for 30 min in 0.1 M PBS. Sections were then incubated for 2 hours at 
room temperature in PBS diluent (3% normal horse serum in 0.1 M PBS containing 
0.25% Triton-100; Sigma-Aldrich). The rabbit polyclonal anti-Fos antibody was diluted 
to 1 : 30 000 in PBS diluent, and the sections were incubated in the primary antibody for 
48 h at 4 °C.  
After two 30-minute rinses in 0.1 M PBS, sections were incubated in a 
biotinylated horse anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA) diluted 
to 1 : 200 in PBS diluent for 2 h at room temperature. The tissue was reacted with an 
avidin–peroxidase conjugate (ABC-Vectastain kit; Vector Laboratories) and PBS 
containing 0.04% 3,30-diaminobenzidene hydrochloride and 0.04% nickel ammonium 
sulphate (Sigma-Aldrich). Sections were mounted on gel-coated slides, processed 
through a series of dehydrating alcohols followed by xylenes, and placed under a 
coverslip with Permount mounting medium.  
Tissue sections were analyzed using an Olympus microscope (BX41) equipped 
for epifluorescence and an Olympus DP70 digital camera with DP MANAGER software 
(v 2.2.1) (Olympus, Center Valley, PA, USA). The PVN was identified using a 
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stereotaxic atlas80 and sampled at three rostral–caudal levels to assess for neuronal 
activation81. Care was taken to ensure that the sections used were from the same rostral–
caudal plane in each brain. Analysis was performed on two sets of tissue for each animal. 
The number of Fos-positive cells was visually quantified by participants blind to the 
experimental conditions using National Institutes of Health IMAGEJ software (NIH, 
Bethesda, MD, USA), and the counts for each PVN subnucleus was averaged for each 
animal. 
Kidney Cortical Preparation 
Kidneys were harvested from animals following completion of acute experimental 
protocols and stored at –80°C. Kidney cortex tissue was homogenized on ice using a 
hand-held pestle in a homogenizing buffer (10 mM triethanolamine, 250 mM sucrose, 
100 mM NaN3, 10 mM PMSF, and 1 mM leupeptin). The resulting homogenate was 
centrifuged at 4,000 g for 10 min at 4°C. The supernatant was collected and centrifuged 
at 17,000 g for 60 min at 4°C. Following centrifugation, the membrane pellet was re-
suspended in 400 l of homogenizing buffer, and protein content was quantified via the 
BCA assay. Membrane preparations were stored at –80°C prior to use in immunoblotting 
studies. 
Determination of Renal Sodium-Chloride Cotransporter Levels 
Protein extracted from membrane preparations of kidney cortex tissue were 
loaded at a concentration of 20 g of protein per lane. Membranes were blocked in 5% 
milk for 1 hour and incubated overnight at 4°C with anti-NCC (1:2,000; Millipore, 
Billerica, MA; cat. no. AB3553) or anti--actin (1:5,000; Sigma, St. Louis, MO; cat. no. 
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A5316) in 0.1% PBS-Tween. Afterwards, membranes were exposed to either a secondary 
horseradish peroxidase donkey anti-rabbit IgG (1:5,000; Promega, Madison, WI; cat. no. 
V7951) or antimouse IgG peroxidase antibody (1:10,000; Sigma; cat. no. A9044) in 0.1% 
PBS-Tween for 1 hour at room temperature. Bound antibodies were visualized using 
chemiluminescence (GE signal enhancer; GE, Buckinghamshire, UK). Densitometric 
analysis was performed using Quantity One software (Bio-Rad, Hercules, CA), and band 
densities were normalized to -actin. 
Statistical Plan/Power Calculations 
 Results are expressed as mean ± SEM. The effects of our experimental 
variable (e.g., VE, ARN ablation) on CV, renal, PVN and/or metabolic parameters at 
different time points are evaluated by comparing the average of these values with the 
respective group control value via a one-way repeated measures ANOVA with Dunnett’s 
post-hoc test. Differences between treatment groups were assessed by two-way repeated 
measures ANOVA with treatment being one fixed effect and time the other, with the 
interaction included. The time (days, etc.) is the repeated factor with Bonferonni’s post-
hoc test. Data was verified for normal distribution and equality of variances. Statistical 
significance is defined as p<0.05. 
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RESULTS 
Effects of ARN Ablation and Physiological Activation of ARN Mechanoreceptors 
and Chemoreceptors on Cardiovascular and Renal Parameters 
Figure 7 illustrates the activation of ARN mechanoreceptors and chemoreceptors 
in response to acute IV 5% BW VE and 1M NaCl infusions respectively. The effects of 
Renal-CAP on mean arterial pressure (MAP), urine output (V), and UNaV are shown in 
Figures 7A and 7B. Our results show that MAP increased in Renal-CAP rats during the 
90-minute recovery period after IV 5% BW VE (Figure 7A). In addition, natriuresis was 
notably reduced during IV VE in Renal-CAP rats compared to sham rats (Figure 7A).  
Figure 7 – Effect of ARN ablation by exposure to capsaicin (Renal-CAP) in male SD rats on changes 
in mean arterial pressure (MAP), urine output (V) and natriuresis (UNaV) evoked by an IV 5% 
bodyweight (BW) volume expansion (VE) (A), and a 2 hour IV 1M NaCl infusion (B). Effect of IV 
5% BW VE (C) and 1M NaCl (D) infusion on renal pelvic pressure (RPP) in anesthetized male SD 
rats. *p<0.05 vs resp. group control/baseline,  p<0.05 vs resp. sham Renal-CAP group value. 
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While IV 5% BW VE resulted in statistically significant differences in the MAP, 
V, and UNaV of Renal-CAP and sham rats (Figure 7A), IV infusion of 1M NaCl caused 
no notable differences between these parameters in Renal-CAP and sham rats (Figure 
7B). In Figure 7A, we noted that Renal-CAP mitigated natriuresis and caused increased 
MAP throughout an IV 5% BW VE. Contrastingly, a 2 hour IV infusion of 1M NaCl 
caused no statistically significant differences between the MAP and V of Renal-CAP and 
sham rats (Figure 7B). Although Renal-CAP and sham rats exhibited changes in UNaV 
that were signficant compared to the respective group control, as marked by *, they do 
not experience changes in UNaV that are statistically significant between one another, as 
indicated by  (Figs. 7A and 7B).  
We also examined the effects of an IV 5% BW VE (Figure 7C) and an IV 1M 
NaCl infusion (Figure 7D) on renal pelvic pressure (RPP) in anesthesized male SD rats. 
Our results show that these anesthesized male SD rats experience statistically significant 
increases in RPP throughout the 30-minute IV VE administration period and during the 
first 30 minutes of recovery (Figure 7C). However during both the control and 2-hour IV 
1M NaCl administration periods, no increases in RPP were observed (Figure 7D). 
PVN Parvoceullar Neuronal Activation in Response to Acute ARN 
Mechanoreceptor and Chemoreceptor Activation.  
In addition to assessing certain cardiovascular and renal parameters in response to 
IV 5% BW VE and IV 1 M NaCl infusion (Figure 7) we also analyzed PVN neuronal 
activation in response to these acute sympathoinhibtory challenges, as illustrated on the 
following page by Figure 8.  
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Figure 8 – A & B (Top) Representative level 2 images of Renal-CAP (A) and sham (B) 5% VE PVN 
Fos+ nuclei. (C) Mean Fos+ parvocellular PVN nuclei averaged across all rostral-caudal levels at 
baseline & 120-minutes post 5% VE or 1M NaCl challenge. 3V – Third Ventricle. Note: *p<0.05 vs 
resp. group control/baseline,  p<0.05 vs resp. sham Renal-CAP group value. 
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 Level 2 representative images of both Renal-CAP and sham rats showed little to 
no activation of PVN parvocellular neurons at baseline prior to IV 5% BW VE (Figs. 8A 
and 8B). 120-minutes post 5% BW VE, however, we observed activation of these 
neurons in both Renal-CAP and sham rats (Figs. 8A & 8B). Critically, PVN parvocellular 
neuron activation was substantially greater in sham rats (Figure 8A) than in Renal-CAP 
rats (Figure 8B). This suggests that the ARN is responsible for inducing the activation of 
PVN parvocellular neurons in response to an acute mechanoreceptor sympathoinhibitory 
challenge, such as an IV 5% BW VE.  
 In Figure 8C, mean Fos+ parvocellular PVN nuclei averaged across all rostral-
caudal levels at baseline & 120-minutes post IV 5% VE or 1M NaCl are shown. At 
baseline, very few Fos+ parvocellular PVN nuclei were observed across all PVN sub-
regions (Figure 8C). This changed 120-minutes post 5% VE and 1M NaCl, as 
significantly greater parvocellular nuclei were quantified in both Renal-CAP and sham 
rats. Figure 8C reaffirms the level 2 images of Figures 8A and 8B, again showing that 
Renal-CAP rats exhibited significantly less Fos+ parvocellular PVN nuclei than sham 
rats across all PVN sub-regions (Figure 8C). This again implies that an intact ARN is 
necessary to evoke PVN parvocellular neuronal activation in response to an acute 
mechanoreceptor stimulus. 
ARN Responses as a Function of High Salt Intake 
 Our results indicate that HS intake (HS; 8% NaCl) evokes both global and renal 
sympathoinhibition in male SD, DSR, and SS-13-BN rats, as demonstrated by Figure 9. 
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Figure 9 – Effect of 21-day high salt intake (HS; 8% NaCl) on: (A) plasma NE (nmol/L), (B) renal NE 
(pg/mg), (C) renal pelvic assay substance-P release (pg/min) in response to NE and (D) NaCl in male 
SD, DSR, SS-13 BN & DSS rats. *p<0.05 vs resp. normal salt intake (NS; 0.6%) group value, p<0.05 
vs resp. DSR NS group value. 
 
 After 21 days on the HS diet previously described, both plasma and renal NE 
levels were reduced in SD, DSR, and SS-13-BN rats (Figs. 9A and 9B). Notably, DSS rats 
on the same 21-day HS diet experienced statistically significant increases in plasma and 
renal NE (Figs. 9A and 9B). In addition, renal pelvic assay substance-P release in 
response to NE was greater in SD and DSR rats on HS diets than those on normal salt 
(NS) diets (Figure 9C). Although DSS rats on HS diets did experience a slight increase in 
NE-evoked substance-P release, this release was attenuated compared to SD and DSR 
rats on the same diet (Figure 9C). Interestingly, substance-P release in response to NaCl 
was unchanged across SD, DSR, and DSS rats regardless of salt diet (Figure 9D). 
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Figure 10 – Natriuresis as a function of (A) renal pelvic pressure or (B) NaCl concentration in male 
SD & DSS rats. Note: #p<0.05 vs resp. baseline value, p<0.05 vs respective NS group value. 
 
 SD rats on HS diets demonstrated increased UNaV in response to RPP that was 
statistically significant with respect to both baseline values and NS group values (Figure 
10A). However, SD rats on NS diets did not demonstrate any statistically significant 
increase in UNaV until a 10mmHg increase in RPP occurred (Figure 10A). In contrast, 
DSS rats demonstrated impaired natriuresis in response to increases in RPP (Figure 10A). 
Also noteworthy, increases in renal pelvic NaCl after HS intake were unable to generate 
enhanced UNaV in both SD and DSS rats (Figure 10B). These results suggest that 
increased RPP, a stimulus of ARN mechanoreceptors, occurs after HS intake in SD rats 
but not after HS intake in DSS rats. 
The Relationship Between Salt Consumption, Sympathetic Nervous System Activity, 
and Regulation of the NCC 
 The effects of HS consumption (HS; 8% NaCl) for 21 days were assessed in 
groups of male rats that were salt-resistant, salt-sensitive, and in SHR rats (Figs. 11 and 
12).  The group of salt-resistant rats was composed of sc saline infused SD rats and DSR 
rats. In these rats, MAP was unaffected by HS intake as illustrated in Figure 11A. In 
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concordance with their salt-resistant phenotype, both sc saline infused SD rats and DSR 
rats downregulated both NCC activity, defined as UNaV to iv HCTZ (Figure 11B), and 
NCC expression in response to HS intake (Figs. 11B and 12A).  
Figure 11 – Effect of 21 day high-salt intake (HS, 8% NaCl) on: A – MAP and B – NCC activity 
(defined as peak natriuresis to HCTZ infusion) in male sc saline or NE (600 ng/min) infused SD rats, 
DSR and DSS rats, Renal-CAP SD rats, and naïve WKY and SHR rats. WKY and SHR rats were 
maintained on normal salt diets. Note: *p<0.05 vs resp. normal salt (NS;0.6% NaCl) value, p<0.05 
vs resp. DSR value, p<0.05 vs SD saline HS value. 
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 Assessed salt-sensitive rats included DSS rats, sc NE (600 ng/min) infused SD 
rats, and Renal-CAP SD rats (Figs. 11-12). In response to HS intake, all three rats 
exhibited statistically significant increases in MAP in comparison to their respective NS 
and salt-resistant counterparts (Figure 11A). Unlike their salt-resistant counterparts, these 
salt-sensitive rats were also unable to downregulate either NCC activity or expression 
following HS intake (Figs 11B and 12A).  
Figure 12 – Effect of 21-day high salt intake (HS, 8% NaCl) on: A – renal NCC protein expression 
and B – representative immunoblots of NCC protein levels in male sc saline or NE infused SD, DSR, 
and DSS rats. Note: *p<0.05 vs resp. normal salt (NS;0.6% NaCl) value, p<0.05 vs resp. DSR value, 
p<0.05 vs SD saline HS value 
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 By comparing naïve WKY and SHR rats maintained on NS diets (NS; 0.6% 
NaCl), we could study MAP and NCC activity in essential neurogenic hypertension 
(Figure 11). We observed that both MAP (Figure 11A) and NCC activity (Figure 11B) 
were enhanced in SHR rats compared to WKY rats, which indicated that the SHR rats 
demonstrated sympathoexcitation.  Taken together, Figures 11 and 12 indicate that in 
both salt-sensitive and essential neurogenic hypertension, the NCC is not downregulated 
as it should be. Representative immunoblots of NCC levels in all salt-resistant and salt-
sensitive rats analyzed are depicted in Figure 12B. These immunoblots bolster the data 
presented Figures 11 and 12A, as NCC protein levels were successfully downregulated in 
salt-resistant rats on HS diets but not in salt-sensitive rats on HS diets (Figure 12B). 
-1 Adrenoreceptors, -Adrenoreceptors, and Their Roles in NCC Regulation 
 Figures 11 and 12 illustrated how MAP, NCC activity, and NCC expression 
changed in groups of salt-resistant and salt-sensitive rats consuming NS and HS (8% 
NaCl) diets. In the following pages, Figures 13-16 show how MAP and protein levels of 
important kinases involved in NCC regulation are impacted by the administration of 
terazosin and propranolol – -1 adrenoreceptor and -adrenoreceptor antagonists 
respectively. Three separate groups of rats were assessed: sc saline infused SD rats on NS 
or HS diets, sc NE infused SD rats on NS or HS diets, and naïve DSS rats on HS diets 
(Figs. 13-16). 
 SD rats subcutaneously infused with saline exhibited no differences in MAP on 
HS (4% NaCl) diets versus NS diets (Figure 13A). In conjunction with either sc terazosin 
(10mg/kg/day) or propranolol (10mg/kg/day) administration, sc saline infused SD rats on 
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HS diets still demonstrated comparable MAP to those on NS diets (Figure 13A). In 
addition, consumption of a HS diet did not affect sodium-evoked downregulation of NCC 
activity in this group of rats. Saline infused SD rats and SD rats infused with a 
combination of saline and either terazosin or propranolol exhibited unaltered baseline 
NCC activity on NS diets and successfully downregulated NCC activity on HS diets 
(Figure 13B). Thus, administration of these adrenoreceptor antagonists did not alter 
baseline MAP, NCC activity, or sodium-evoked suppression of NCC activity in sc saline 
infused SD rats (Figure 13). In addition, these rats responded to HS intake by suppressing 
the expression of both the NCC and the important kinases that regulate it (Figs. 14-16).   
Figure 13 – Effect of 21 day 4% NaCl intake (High Salt) in sc saline or NE infused SD rats and male 
DSS rats receiving sc terazosin (Teraz; 10mg/kg/day) or propranolol (Pro; 10mg/kg/day) on MAP (A) 
and NCC activity (B) (peak natriuresis to HCTZ). *p<0.05 vs resp. normal salt (NS) group, p<0.05 
vs resp. HS group value.  
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Figure 14 – Effect of 21 day 4% NaCl intake (High Salt) in sc saline or NE infused SD rats and naïve 
male DSS rats receiving sc terazosin (Teraz; 10mg/kg/day) or propranolol (Pro; 10mg/kg/day) on 
NCC expression (A) and pNCCT58 expression (B). *p<0.05 vs resp. normal salt (NS) group, p<0.05 
vs resp. HS group value. 
 
 In contrast, sc NE infused SD rats exhibited increased MAP as a function of HS 
intake (Figure 13A). Notably, administration of either terazosin or propranolol eliminated 
these increases in MAP and abolished the salt-sensitive of blood pressure in sc NE 
infused SD rats on HS diets (Figure 13A).  
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In these SD rats, NE infusion eliminated the ability of salt-intake to downregulate 
NCC activity, NCC expression, and the expression of the following proteins involved in 
NCC activation or regulation: pNCC, OxSR1, pOxSR1, and STE20/SPS1-related 
proline/alanine-rich kinase (SPAK) (Figs. 13-16). NE binds to renal adrenoreceptors and 
causes activation of WNK, which phosphorylates both SPAK and OxSR168,70. These 
kinases then phosphorylate NCC, upregulating it and making it active68,70.  
Figure 15 – Effect of 21 day 4% NaCl intake (High Salt) in sc saline or NE infused SD rats and naïve 
male DSS rats receiving sc terazosin (Teraz; 10mg/kg/day) or propranolol (Pro; 10mg/kg/day) on 
OxSR1 expression (A) and pOxSR1 expression (B). *p<0.05 vs resp. normal salt (NS) group, p<0.05 
vs resp. HS group value. 
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Critically, selective -1 adrenoreceptor via terazosin administration restored not 
only downregulation of NCC activity in response to salt-intake, but also downregulation 
of NCC, pNCC, OxSR1, pOxSR1, and SPAK expression (Figs. 13-16). Propranolol 
administration eliminated NE-evoked increases in MAP (Figure 13A). Unlike terazosin, 
propranolol was unable to reestablish sodium-evoked suppression of NCC activity or 
expression (Figs. 13B and 14A). It was similarly unsuccessful in restoring sodium-
evoked suppression of pNCC, OxSR1, and pOxSR1 (Figs. 14B-15).  
Figure 16 – Effect of 21 day 4% NaCl intake (High Salt) in sc saline or NE infused SD rats and naïve 
male DSS rats receiving sc terazosin (Teraz; 10mg/kg/day) or propranolol (Pro; 10mg/kg/day) on 
STE20/SPS1-related proline/alanine-rich kinase (SPAK)  expression (A). Sample Immunoblots (B). 
*p<0.05 vs resp. normal salt (NS) group, p<0.05 vs resp. HS group value. 
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 In naïve DSS rats on HS diets sc terazosin administration blunted the observed 
increases in MAP (Figure 13A), indicating terazosin’s ability to attenuate the salt-
sensitivity of blood pressure in naïve DSS rats. In contrast, propranolol was unable to 
attenuate the salt-sensitivity of blood pressure in DSS rats on HS diets, given that these 
rats still experienced notable increases in MAP despite propranolol administration 
(Figure 13A).  
Just as propranolol was unable to restore sodium-evoked suppression of NCC 
activity or expression in NE infused SD rats, DSS rats receiving the -adrenoreceptor 
antagonist did not regain sodium-evoked suppression of either NCC parameter (Figs. 13B 
and 14A). Phosphorylated NCC, OxSR1, and pOxSR1 remained upregulated in DSS rats 
receiving sc propranolol (Figs. 14B-15). Interestingly, SPAK expression was 
downregulated after propranolol administration in both sc NE infused SD rats and naïve 
male DSS rats (Figure 16A). Sample immunoblots (Figure 16B) illustrate terazosin’s 
ability and propranolol’s inability to restore sodium-evoked suppression of NCC, pNCC, 
and other kinase levels. 
Antagonism of the Renal -1 Adrenoreceptor in Established Salt-Sensitive 
Hypertension and Established Essential Neurogenic Hypertension 
 We analyzed sc NE infused SD rats and SHR rats to assess terazosin’s effects on 
two forms of established hypertension: salt-sensitive hypertension (sc NE infused SD) 
and essential neurogenic hypertension (SHR) (Figure 17). During a 42-day experimental 
period, SD rats on NS and HS diets (HS; 4% NaCl) received sc NE for the first 21 days. 
These rats consequently developed salt-sensitive hypertension. To test terazosin’s ability 
on established salt-sensitive hypertension, some of these sc NE infused SD rats received 
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sc terazosin during days 22-42 of the experimental period (Figure 17). We examined 
terazosin’s effects on established essential neurogenic hypertension by comparing Naïve 
NS (NS; 0.6% NaCl) fed SHR rats to those receiving the -1 antagonist subcuteanously 
(Figure 17). Critically, terazosin administration lowered blood pressure and reduced NCC 
activity in established essential neurogenic hypertension. In addition, it reestablished 
sodium-evoked suppression of NCC activity and abolished salt-sensitivity of blood 
pressure in established NE-evoked salt-sensitive hypertension (Figure 17). 
Figure 17 – Effect of sc terazosin (10mg/kg/day) on: MAP (A) and peak natriuresis (UNaV) to iv 
HCTZ (B) in groups of naïve normal salt (NS; 0.6% NaCl) fed male SHR and SD rats receiving 
either NS or high salt (HS; 4% NaCl) during 42-day sc saline or NE (600 ng/min) infusion or 42-day 
NE infusion in combination with 21-day sc terazosin for days 22-42. *p<0.05 vs resp. group NS (0.6% 
NaCl) value, p<0.05 vs HS NE. 
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DISCUSSION 
 Through a novel experimental paradigm and refined analyses of the 
cardiovascular and renal systems, our laboratory has produced important evidence 
regarding the respective roles of the ARN and the NCC in the regulation of fluid and 
electrolyte homeostasis. Acutely, we have demonstrated a role of the ARN’s 
mechanoreceptors in mediating a crucial sympathoinhibitory reno-renal renal reflex that 
maintains blood pressure and increases UNaV in response to an IV 5% BW VE: an acute 
sympathoinhibitory challenge that is mechanoreceptor-specific82–86. Chronically, our 
experiments have yielded data that suggests that ARN mechanoreceptors are activated by 
long-term HS intake in salt-resistant rats, but not salt-sensitive rats. Furthermore, our 
results have indicated that this same mechanoreceptor-driven ARN sympathoinhibitory 
reno-renal reflex indirectly influences NCC activity and expression. Collectively, our 
experiments have provided innovative mechanistic information on both the ARN and 
NCC, and have provided insight into new a new therapeutic target, the DCT -1 
adrenoreceptors, that can be used to treat sympathetically-driven hypertension in humans. 
Acute Role of the ARN 
 
 Mechanoreceptors in the ARN are activated by RPP increases of 2.5 to 3 mmHg 
increments19,44,79,87–90, and are important in conducting the ARN sympathoinhibitory 
reno-renal reflex that exerts a tonic inhibition on efferent RSNA44. Through 
administration of an acute IV 5% BW VE, we isolated renal mechanoreceptors and 
activated them by increasing total body fluid and sodium content, which increased 
RPP19,88,89. In contrast, we used a 1M NaCl infusion to isolate renal chemoreceptors. This 
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infusion activated the chemoreceptors by increasing total body and urinary sodium, 
neither of which affected RPP19,88,89. Both of these infusion protocols have been 
established as acute sympathoinhibitory challenges82–86 that are uniquely able to activate 
ARN mechanoreceptors or chemoreceptors. 
  Our data suggests that ARN mechanosensitive receptors have a significant role in 
mediating an acute ARN sympathoinhibitory reno-renal reflex that regulates both 
natriuresis and MAP. While previous studies, notably those conducted by Dr. Ulla Kopp, 
examined the effects and activation mechanisms of renal mechanosensory nerves44,85,90,91, 
our experiment analyzed how ARN mechanoreceptor-dependent functions were affected 
by a novel ARN ablation technique – Renal-CAP73 .  
 By comparing the responses of conscious Renal-CAP and sham surgery rats 
during and after acute IV 5% BW VE74,82,84,92,93 (ARN mechanoreceptor stimulus) and iv 
1M NaCl infusion85,86 (ARN chemoreceptor stimulus), we used a new experimental 
paradigm to assess how changes in MAP, V, and UNaV were acutely affected in 
conscious, ARN denervated rats. This is the first time that a physiological role of the 
ARN sympathoinhibitory reno-renal reflex has been demonstrated in a conscious animal. 
 Furthermore, our quantification of PVN parvocellular neuronal activation at 
baseline and 120-minutes post-VE revealed new visual evidence that shows that IV 5% 
BW VE activates PVN inhibitory neurons that modulate CNS sympathetic outflow, and 
thus regulate both blood pressure and UNaV. These findings illustrate the acute role of 
ARN mechanoreceptors in maintaining fluid and electrolyte homeostasis through the 
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sympathoinhibitory reno-renal reflex, and highlight its protective abilities against excess 
efferent SNSA.  
Chronic Role of the ARN   
The ARN mechanoreceptor-driven sympathoinhibitory reno-renal reflex is not 
only significant during acute sympathoinhibitory challenges, but also in response to 
chronic HS intake. Our results indicated that salt-resistant rats depend on the 
mechanosensitive ARN sympathoinhibitory reno-renal reflex to regulate blood pressure 
during chronic HS consumption. This relates to Dr. Kopp’s previous findings concerning 
the ability of ARNs in normotensive rats to inhibit excessive efferent SNSA43,44,91. In 
contrast, salt-sensitive rats suffer from an impairment in the ARN sympathoinhibitory 
reno-renal reflex which prevents them from controlling blood pressure in response to 
chronic HS intake. 
These findings suggest that ARN mechanoreceptors are activated by HS intake in 
salt-resistant rats, potentially due to increased RPP resulting from increased urine output. 
Given that the urine flows from renal pelvis of the kidney to reach the bladder, where 
urine is stored94,95, it is logical that increased urine output would require increased urine 
volume flowing through the renal pelvis and, therefore, lead to increased RPP. 
  The enhanced mechanosensitive propagation of the ARN sympathoinhibitory 
reno-reflex in response to HS intake is shown to be vital for salt-resistant rats to regulate 
blood pressure and UNaV. Clinically, patient screening for this protective ARN reno-
renal reflex can prevent its unnecessary removal and, by doing so, ensure a preexisting 
mechanism of regulating efferent SNSA is kept intact. 
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The NCC and Blood Pressure 
The NCC plays a critical role in fine-tuning the sodium reabsorption that occurs 
after the tubuloglomerular feedback that occurs in the proximal convoluted tubule54. The 
NCC is regulated by a complex and multifaceted kinase network, which consists of the 
proteins WNK, SPAK, and OxSR170,96–104. Our data provides evidence that the NCC is 
indirectly affected by the mechanoreceptor-driven ARN sympathoinhibitory reno-renal 
reflex through a NE-1-adrenoreceptor gated signal transduction pathway. It has been 
established that the mechanosensitive ARN sympathoinhibitory reno-renal reflex 
suppresses excess efferent RNSA42,44–49,91.  
Our data suggests that the efferent renal nerve, which projects from the CNS back 
to the kidney41,94, releases NE that binds to -1 adrenoreceptors in the DCT. This binding 
results in a kinase cascade in which a now activated WNK1 phosphorylates the 
intermediary kinases SPAK and OxSR1, the latter of phosphorylates stationary NCCs and 
increases their activity70,96–104. Since the mechanosensitive ARN sympathoinhibitory 
reno-renal reflex attenuates central sympathetic outflow in response to chronic HS 
consumption, it prevents excess efferent RSNA and, thus, prevents excessive renal NE 
release and the aberrant NCC-mediated sodium reabsorption that would consequently 
occur. On the following page, Figure 18 illustrates the modulation of efferent RNSA by 
the ARN sympathoinhibitory reno-renal reflex in response to HS intake at the level of 
organ systems and at DCT cells. 
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Figure 18 – Suppression of Central Sympathetic Outflow by ARN in response to HS intake (Right) & 
Resulting Effects on the Proposed Norepinephrine-1-Adrenoreceptor Gated OxSR1 Pathway 
Regulating NCC Activity and Expression (Left). (Kidney Image Taken From 105) 
 
Our experiments have demonstrated the ability of a selective 1-adrenoreceptor 
antagonist (terazosin) to mitigate the salt-sensitivity of blood pressure in salt-sensitive 
rats and shown that terazosin can restore sodium-evoked suppression of NCC activity and 
sodium-evoked suppression of NCC, pNCC, OxSR1, and pOxSR1. Critically, we 
demonstrated the ability of terazosin administration to lower blood pressure and reduce 
NCC activity in rats with established salt-sensitive hypertension and with established 
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essential neurogenic hypertension. This provides important evidence that 1-
adrenoreceptor antagonism is a viable therapeutic approach to precisely treat salt-
sensitive and essential neurogenic hypertension. The need to identify novel therapeutic 
targets to treat hypertension is underscored by the fact the development of anti-
hypertensive drugs has not been very productive106. Given the incidence of individuals 
with salt-sensitive or essential neurogenic hypertension17,30,107–113, our findings hold 
significance in revealing that 1-adrenoreceptor antagonism as a precise therapeutic 
mechanism that can potentially be used to treat these hypertensive individuals.    
Overall Significance, Limitations, and Future Considerations 
 Our results have demonstrated that the mechanoreceptor-based ARN 
sympathoinhibitory reno-reflex plays a role in PVN neuronal activation and maintenance 
of blood pressure in salt-resistant rats, and that failure of this pathway occurs in rats with 
salt-sensitive and essential neurogenic hypertension. These findings show that increased 
propagation of the mechanosensitive ARN sympathoinhibitory reno-reflex occurs in 
response to chronic HS intake, and that this reno-reflex is necessary to regulated blood 
pressure and natriuresis. In a clinical context, patient screenings for this protective ARN 
reno-renal reflex can prevent it from being removed and consequently ensure patients 
keep a preexisting mechanism of regulating efferent SNSA in place. 
 One limitation our laboratory faced is the lack of pharmacological antagonists for 
either mechanoreceptors or chemoreceptors. Thus, our experiments necessitated the use 
of physiological manipulations, IV 5% BW VE and IV 1M NaCl infusion, to activate and 
assess mechanoreceptors and chemoreceptors respectively. Should mechanoreceptor and 
  44 
chemoreceptor pharmacological antagonists be developed and become available, 
additional studies will be conducted to ensure our results are valid. It should also be noted 
that our quantification of active PVN inhibitory interneurons was limited through Fos+ 
immunohistochemistry. This is primarily because Fos indicates activation and does not 
stain based on the phenotypes of active cells. Therefore, we are unable to definitively say 
that the activated neurons we quantified are inhibitory or excitatory because there Fos+ 
only indicates activation, not cell phenotype. 
We have also indicated the ARN’s important role in facilitating sodium-evoked 
maintenance of chronic NCC activity by regulating sympathetic tone, and that this 
regulation occurs via a NE-1-adrenoreceptor-WNK1-OxSR1 pathway70,96–104. In 
addition, our data presents compelling evidence that NCC regulation is hampered in salt-
sensitive rats, which are unable to modulate efferent RSNA due to an impaired 
mechanosensitive ARN sympathoinhibitory reno-renal reflex.   
Another limitation faced involved our ability to isolate physiological NCC 
activity. To selectively examine physiological NCC activity, we administered prior ENaC 
blockade (achieved through amiloride administration) and continued ENaC blockade 
during NCC inhibition (achieve through amilorideHCTZ administration). In addition, we 
were limited in that we signified NCC phosphorylation as an indicator of NCC activity. 
We understand that the weakness of using this experimental protocol and assessment 
technique is that they do not directly assess NCC mediated sodium transport. However, 
these techniques have been widely used and are the only experimental approaches 
available to evaluate NCC activity in vivo114–119.  
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We have provided important evidence on potential treatments for salt-sensitive 
and essential neurogenic hypertension. Our data provides insight into  -1 adrenoreceptor 
antagonism as a new therapeutic mechanism that can increase activity of the 
mechanosensitive ARN sympathoinhibitory reno-renal reflex and natriuresis in 
individuals with salt-sensitive or essential neurogenic hypertension. Since anti-
hypertensive drug development has been unproductive106, our data is significant in 
revealing a new therapeutic mechanism that can treat these hypertensive individuals in a 
more precise and effective manner.  
In addition, our results have demonstrated the potential therapeutic benefits of 
renal denervation in humans. Considering the role that excessive efferent RSNA has in 
NCC upregulation and hypertension development, ablation of renal sympathetic nerves is 
a worthwhile treatment avenue to consider. Hypertensive individuals who suffer from 
impaired or nonexistent mechanosensitive ARN sympathoinhibitory reno-renal reflex 
activity could greatly benefit from ablation of renal sympathetic nerves. In these 
hypertensive individuals, impairment of the mechanosensitive ARN sympathoinhibitory 
reno-renal reflex would be measured as UNaV in response to clinically manipulated 
increases in RPP.  
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